Browse Studies — Arctuva

Phase 1

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-…

LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma+10 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Dren BioNCT05475925

Phase 1

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

To find the best method of administering NK cells in patients with recurrent glioblastoma.

Phase 1NK CellIL13Ra+4 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07579208

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the infor…

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more